Last Update 05 Jun 26
MGNX: Antibody Drug Conjugate Data And Deals Will Drive Future Upside
Narrative Update: MacroGenics
Analysts have raised their price targets on MacroGenics by $1 to $2, citing updated views on the company's antibody drug conjugate potential and recent deal activity as key reasons for the higher valuation outlook.
Analyst Commentary
Recent Street research on MacroGenics has focused on price target changes, rating shifts and the role of the antibody drug conjugate pipeline in shaping expectations for future execution and potential valuation outcomes.
Bullish Takeaways
- Bullish analysts have raised price targets by about $1 to $2 in recent updates, reflecting a view that recent deal activity and the antibody drug conjugate pipeline could support a higher valuation if execution stays on track.
- One price target move from $3 to $4 followed the Q4 report, with analysts pointing to antibody drug conjugate data expected in 2026 as a possible source of upside for the stock if results align with current expectations.
- The upgrade in rating from Neutral to Buy by a bullish analyst group after the Tubulus deal highlights confidence that recent corporate actions could improve the company’s growth profile and strengthen its competitive position in antibody drug conjugates.
- Positive commentary ties the higher targets to the potential for clearer clinical data and deal synergies over time, which, in a constructive case, could support re-rating if the company delivers on development milestones.
Bearish Takeaways
- Even within more positive reports, there is an implicit acknowledgment that much of the thesis depends on antibody drug conjugate data that is not expected until 2026, which introduces timing risk for investors looking for nearer term catalysts.
- Higher price targets and rating upgrades still assume the company can execute on recent deals and clinical plans, leaving room for disappointment if integration, trial design or regulatory steps do not go as planned.
- Bullish analysts focusing on potential upside also underline that the story is still heavily tied to future clinical outcomes, which may lead more cautious investors to wait for clearer efficacy and safety readouts before assigning materially higher valuations.
- The emphasis on a single therapeutic area as a key upside driver means that any weaker than expected antibody drug conjugate data could weigh on sentiment, and may limit how much multiple expansion some bearish analysts are willing to factor in today.
What's in the News
- MacroGenics reported that the U.S. Food and Drug Administration removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab. The decision allows new participants to enroll under a revised protocol that adds risk mitigation measures for potential hematologic and cardiac toxicities. Source: Company product-related announcement.
- The LINNET study is set to evaluate single agent lorigerlimab, which targets PD-1 and CTLA-4, in up to approximately 60 eligible participants with platinum-resistant ovarian cancer or clear cell gynecologic cancer who have received one or more prior lines of therapy. Source: Company product-related announcement.
- MacroGenics disclosed that 41 participants have been dosed in the LINNET study so far, and over 300 participants have been dosed across all prior Phase 1 and Phase 2 lorigerlimab studies. This provides investors with additional context on the clinical experience with this asset. Source: Company product-related announcement.
Valuation Changes
- Fair Value: $6.75 remains unchanged, indicating no adjustment to the central valuation estimate in this update.
- Discount Rate: 7.29% has shifted marginally lower from 7.29%, reflecting only a very small technical adjustment in the risk assumption.
- Revenue Growth: The long term revenue growth assumption is kept at a decline of 2.52%, with no change between the prior and updated figures.
- Net Profit Margin: 19.04% is slightly higher than the prior 18.87%, implying a modestly stronger long term profitability assumption.
- Future P/E: 19.26x is fractionally lower than the previous 19.43x, pointing to a very small reduction in the valuation multiple used in the model.
6 viewsusers have viewed this narrative update
Key Takeaways
- Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.
- A robust pipeline and financial sustainability support continued R&D efforts, reinforcing prospects for growth if new treatments prove effective.
- Rising R&D costs, potential liquidity risks, and strategic shifts in program development highlight financial and operational challenges for MacroGenics.
Catalysts
About MacroGenics- A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
- Completion of enrollment in the LORIKEET Phase 2 trial for lorigerlimab, with anticipated updates in the second half of 2025, could drive investor expectations for future revenue growth if promising clinical results are obtained.
- Initiation of the LINNET Phase 2 study in mid-2025, targeting unmet needs in ovarian and gynecologic cancers, positions MacroGenics for potential future earnings improvement if successful trial outcomes lead to product approvals.
- The promising clinical development of MGC026, an ADC targeting B7-H3, with potential dose expansion planned for 2025, suggests future revenue potential if the treatment shows efficacy and safety in solid tumors.
- The ongoing Phase 1 trial for MGC028 and the anticipated IND submission for MGC030 in 2026 indicate a robust pipeline that could enhance revenue and earnings if these drugs prove effective and secure regulatory approval.
- The $201.7 million cash balance, anticipated to support operations into the second half of 2026, underscores the company’s ability to sustain its R&D activities, enhancing future revenue potential from successful product development.
MacroGenics Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming MacroGenics's revenue will decrease by 2.5% annually over the next 3 years.
- Analysts are not forecasting that MacroGenics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate MacroGenics's profit margin will increase from -44.8% to the average US Biotechs industry of 19.0% in 3 years.
- If MacroGenics's profit margin were to converge on the industry average, you could expect earnings to reach $27.7 million (and earnings per share of $0.43) by about June 2029, up from -$70.4 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.5x on those 2029 earnings, up from -3.8x today. This future PE is greater than the current PE for the US Biotechs industry at 16.6x.
- Analysts expect the number of shares outstanding to grow by 0.57% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.29%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- MacroGenics reported a net loss of $67 million for the year-ended December 31, 2024, compared to a net loss of $9.1 million for 2023, which could impact future earnings and overall financial health.
- The company's research and development expenses increased to $177.2 million in 2024 from $166.6 million in 2023, indicating rising costs that could pressure net margins and profitability.
- MacroGenics is exploring alternatives for partnering its vobra duo program after deciding not to pursue further internal development, which reflects uncertainty in generating future revenue from this asset.
- The company anticipates that its cash reserves and future partner payments will support operations only until the second half of 2026, indicating potential liquidity risks and dependency on successful future collaborations or funding.
- The ongoing clinical trials and development of new candidates are subject to the usual risks associated with clinical research, including unpredictable outcomes and approval challenges, which could impact future revenue streams.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $6.75 for MacroGenics based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $4.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $145.5 million, earnings will come to $27.7 million, and it would be trading on a PE ratio of 19.5x, assuming you use a discount rate of 7.3%.
- Given the current share price of $4.25, the analyst price target of $6.75 is 37.0% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on MacroGenics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
US$4
FV
8.3% overvalued intrinsic discount17
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
US$9
FV
51.9% undervalued intrinsic discount27
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative